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ABSTRACT
Objectives: Gestational diabetes mellitus is a carbohydrate intolerance that occurs during pregnancy. Various inflammatory 
mediators are considered to be risk factors leading to GDM development. Among them are pro-inflammatory cytokines, 
such as IL16 and IL18. The aim of this study was to examine the association between IL16 and IL18 polymorphisms and GDM.
Material and methods: This study included 204 pregnant women with GDM and 207 pregnant women with normal 
glucose tolerance (NGT). All samples were genotyped in duplicate using allelic discrimination assays with TaqMan® probes.
Results: We observed that there was a decreased frequency of IL16 rs4778889 CC genotype carriers among women with 
GDM (CC vs. CT + TT: OR = 0.14; 95% CI = 0.02–1.15; p = 0.034). However, there was no significant difference in the distri-
bution of alleles (C vs. T: OR = 0.81; 95% CI = 0.54–1.21; p = 0.30). There was a decreased frequency of the IL18 rs187238 G 
allele among GDM women (G vs. C: OR = 0.71; 95% CI = 0.53–0.96; p = 0.027). We also observed a decreased frequency of 
the IL18 rs1946518 T allele among women with GDM; however, this difference had only borderline statistical significance. 
We observed an association between IL18 rs187238, rs1946518 and BMI in pregnant women.
Conclusions: The results of this study suggest that IL18 rs187238 and rs1946518 polymorphisms may be associated with 
an increased risk of GDM as well as with BMI in pregnant women.
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INTRODUCTION
Gestational diabetes mellitus (GDM) is a carbohydrate 
intolerance caused by decreased insulin synthesis and ac-
tion, which is diagnosed in the second or third trimester of 
pregnancy. The important risk factors of GDM include ad-
vanced maternal age, obesity and a family history of type 2 
diabetes (T2DM) [1, 2]. This disorder is associated with sev-
eral maternal and neonatal metabolic and cardiovascular 
complications [3, 4]. Recent studies suggest that genetic 
factors play important role in pathogenesis of GDM [5]. 
The role of the inflammatory response in the pathogenesis 
of GDM has been recently investigated [6]. Various inflam-
matory mediators are considered to be risk factors leading 
to GDM development [7, 8], including cytokines. Cytokines 
are a group of proteins produced by cells involved in the 
immune response, and they act as immune regulators and 
mediators. Cytokines may perform both pro-inflammatory 
as well as anti-inflammatory actions. Diabetes, carbohydrate 
intolerance and insulin resistance are associated with an in-
creased synthesis of pro-inflammatory cytokines, such as 
IL16 and IL18 [9]. Recent studies suggest that pro-inflamma-
tory cytokines also play an important role in GDM pathogen-
esis [10]. The inflammatory response and an imbalance be-
tween pro-inflammatory and anti-inflammatory cytokines 
may lead to the development of pregnancy-induced glucose 
intolerance and insulin resistance [11]. Previous studies 
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have revealed that cytokine production may be associated 
with polymorphisms in cytokine-encoding genes [12]. 
These polymorphisms may alter gene expression and cy-
tokine synthesis, and have been investigated in patients 
with type 1 and type 2 diabetes [13]. These polymorphisms 
may be associated with increased IL16 and IL18 synthesis in 
some patients and enhanced inflammatory response. Previ-
ous studies have shown that these polymorphisms may be 
associated with increased risk of inflammatory diseases [14]. 
The aim of this study was to examine the association be-
tween IL16 and IL18 gene polymorphisms and GDM.
MATERIAL AND METHODS
Patients
This study included 204 pregnant women with GDM and 
207 pregnant women with normal glucose tolerance (NGT). 
The diagnosis of GDM was based on a 75 g oral glucose 
tolerance test (OGTT) at 24–28 weeks’ gestation, accord-
ing to the International Association of Diabetes and Preg-
nancy Study Groups (IADPSG) criteria [15]. The diagnosis of 
GDM was made when one of the following plasma glucose 
values in the OGTT was met or exceeded: fasting plasma 
glucose of 92 mg/dL (5.1 mmol/L); 1 h plasma glucose of 
180 mg/dL (10.0 mmol/L); 2 h plasma glucose of 153 mg/dL 
(8.5 mmol/L) [15]. Exclusion criteria were: type 1 and type 2 
diabetes, autoimmune and inflammatory diseases, neoplas-
tic diseases and chronic infections. Among the pregnant 
women with GDM, 152 (75%) were treated with diet control 
alone throughout the pregnancy, whereas the remaining 
52 (25%) were treated with diet control and insulin until 
delivery. The study was approved by the ethics committee 
in Pomeranian Medical University, Szczecin, Poland, and 
written informed consent was obtained from all subjects.
Methods
All samples were genotyped in duplicate using allelic 
discrimination assays with TaqMan® probes (Applied Bio- 
systems, Carlsbad, California, USA) on a Real-Time PCR 
Detection System (Applied Biosystems). To discriminate 
the IL16 rs4778889 and IL18 rs187238, rs1946518 gene 
polymorphisms, TaqMan® Pre-Designed SNP Genotyping 
Assays were used (the assay IDs were C__31837550_10, 
C___2408543_10 and C___2898460_10 respectively). Ap-
propriate primers were included and fluorescently labelled 
(FAM and VIC) MGB™ probes were used to detect the alleles.
Statistical analysis
The agreement of the genotype distribution with the 
Hardy-Weinberg equilibrium (HWE) was assessed using the 
exact test. A chi-square test was used to compare genotype 
and allele distributions between groups. Clinical parame- 
ters were compared between genotype groups using the 
Mann-Whitney test. Statistical significance was assessed at 
the value of p < 0.05.
RESULTS
Clinical parameters of women with and without GDM 
are shown in Table 1. The family history of type 2 diabetes 
in women with GDM was noted in 82 cases (40%). 
The studied genotypes were distributed according to 
HWE and are shown in Table 2.
We observed that there was a decreased frequency 
of IL16 rs4778889 CC genotype carriers among women 
with GDM (CC vs. CT + TT: OR = 0.14; 95% CI = 0.02–1.15; 
p = 0.034). However, there was no significant difference in 
the distribution of alleles (C vs. T: OR = 0.81; 95% CI = 0.54–
–1.21; p = 0.30).
Regarding the IL18 rs187238 polymorphism, there was 
a decreased frequency of the G allele among GDM women 
(G vs. C: OR = 0.71; 95% CI = 0.53–0.96; p = 0.027; 
GG vs. CG + CC: OR = 0.49; 95% CI = 0.25–0.97; p = 0.037). We 
also observed a decreased frequency of the IL18 rs1946518 T 
allele among women with GDM; however, this difference 
had only borderline statistical significance (T vs. G: OR = 0.77; 
95% CI: 0.59–1.02; p = 0.071; Table 2).
Additionally, we examined the association between the 
studied genotypes and the following clinical parameters in 
women with GDM: body mass before pregnancy, body mass 
at birth, body mass increase during pregnancy, BMI (body 
mass index) before pregnancy, BMI at birth, BMI increase 






Mean ± SD Mean ± SD
Age [years] 29.2 ± 5.0 31.7 ± 4.5
Height [cm] 165.5 ± 5.7 164.7 ± 5.9
Body mass before pregnancy [kg] 63.3 ± 12.4 68.3 ± 16.4
Body mass at birth [kg] 78.1 ± 14.2 79.5 ± 17.1
Body mass increase during 
pregnancy [kg] 14.8 ± 5.4 11.1 ± 5.2
BMI before pregnancy [kg/m2] 23.0 ± 4.0 25.1 ± 5.5
BMI at birth [kg/m2] 28.4 ± 4.5 29.3 ± 5.9
BMI increase during pregnancy 
[kg/m2] 5.4 ± 1.9 4.1 ± 2.0
Current number of pregnancy 1.8 ± 1.1 2.0 ± 1.0
HbA1c [%] – 5.56 ± 0.48
Daily insulin requirement [unit] – 5.28 ± 11.45
Childbirth [weeks] 39.1 ± 1.6 38.5 ± 1.9
Newborn body mass [g] 3362 ± 530 3265 ± 631
APGAR (0–10) 9.9 ± 0.4 9.7 ± 1.0
BMI — body mass index; HbA1c — glycated haemoglobin
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during pregnancy, glycated haemoglobin HbA1c, daily in-
sulin requirement, duration of pregnancy, newborn body 
mass and Apgar score. Among women with the CT genotype 
IL16 rs4778889, we observed a lower increase of body mass 
and BMI during pregnancy compared with the TT genotype 
(Table 3). Women with the CG genotype IL18 rs187238 had 
a higher increase of body mass and BMI during pregnancy 
than the CC genotype (Table 4). Women with the GT genotype 
IL18 rs1946518 had a higher body mass and BMI before preg-
nancy and at birth compared with the GG genotype (Table 5).
In the multivariate logistic regression analysis, taking 
into account maternal age, BMI before pregnancy as well 
as IL18 rs1946518 and IL16 rs4778889 polymorphisms we 
examined the independent risk factors of GDM. In this analy-
sis, older age and higher BMI before pregnancy were inde-
pendent significant predictors of a higher risk of GDM, while 
higher number of IL18 rs1946518 T alleles was a protective 
factor against GDM (Table 6). 
DISCUSSION
In this study we examined the associations between 
IL16 and IL18 gene polymorphisms and GDM. Our results 
have indicated decreased frequency of IL16 rs4778889 CC 
genotype among women with GDM, decreased frequency 
of the IL18 rs187238 G allele, as well as decreased frequency 
of the IL18 rs1946518 T allele; however, this difference had 
borderline statistical significance (p = 0.071). In the mul-
tivariate logistic regression analysis older age and higher 
Table 2. Distribution of IL16 and IL18 genotypes and alleles in women with GDM and controls
Control group GDM
p value^ OR (95% CI) p value^
N % N %
IL16 rs4778889 genotype
TT 153 73.91% 155 75.98%
0.11
CC + CT vs. TT 0.90 (0.57–1.40) 0.63
CT 47 22.71% 48 23.53% CC vs. CT + TT 0.14 (0.02–1.15) 0.034
CC 7 3.38% 1 0.49% CC vs. TT 0.14 (0.02–1.16) 0.035
CT vs. TT 1.01 (0.64–1.60) 0.97
CC vs. CT 0.14 (0.02–1.18) 0.039
Allele
T 353 85.27% 358 87.75%
C vs. T 0.81 (0.54–1.21) 0.30
C 61 14.73% 50 12.25%
IL18 rs187238 genotype
CC 94 45.41% 109 53.43%
0.069
GG + CG vs. CC 0.73 (0.49–1.07) 0.10
CG 86 41.55% 81 39.71% GG vs. CG + CC 0.49 (0.25–0.97) 0.037
GG 27 13.04% 14 6.86% GG vs. CC 0.45 (0.22–0.90) 0.022
CG vs. CC 0.81 (0.54–1.22) 0.32
GG vs. CG 0.55 (0.27–1.12) 0.098
Allele
C 274 66.18% 299 73.28%
G vs. C 0.71 (0.53–0.96) 0.027
G 140 33.82% 109 26.72%
IL18 rs1946518 genotype
GG 62 29.95% 73 35.78%
0.15
TT + GT vs. GG 0.77 (0.51–1.16) 0.21
GT 105 50.72% 105 51.47% TT vs. GT + GG 0.61 (0.36–1.04) 0.069
TT 40 19.32% 26 12.75% TT vs. GG 0.55 (0.30–1.00) 0.051
GT vs. GG 0.85 (0.55–1.31) 0.46
TT vs. GT 0.65 (0.37–1.14) 0.13
Allele
G 229 55.31% 251 61.52%
T vs. G 0.77 (0.59–1.02) 0.071
T 185 44.69% 157 38.48%
^χ2 test  
HWE: control group p = 0.17, GDM p = 0.32 for IL16 rs4778889 
HWE: control group p = 0.35, GDM p = 1.00 for IL18 rs187238 
HWE: control group p = 0.78, GDM p = 0.24 for IL18 rs1946518
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BMI before pregnancy were independent significant pre-
dictors of a higher risk of GDM, while higher number of 
IL18 rs1946518 T alleles was a protective factor against GDM.
It has been shown that IL18 promoter gene polymor-
phisms rs187238 and rs1946518, may influence promoter 
activity and IL18 production [12, 16, 17]. Previous studies 
have indicated that IL16 and IL18 are pro-inflammatory 
cytokines involved in the pathogenesis of diabetes [13, 
18–20]. The significant role of low-grade inflammation has 
been confirmed in type 2 diabetes. Due to the similarity 
between T2DM and GDM, and the association between 
T2DM and inflammation, it has been hypothesised that 
inflammation could also be implicated in the pathophysiol-
ogy of GDM [6, 7]. Several studies have examined cytokine 
production in pregnant women and it has been shown that 
during pregnancy, the imbalance between the production 
of anti-inflammatory and pro-inflammatory cytokines may 
induce low-grade inflammation and insulin resistance [21].
Previous studies have indicated that women with GDM 
have increased plasma IL16 and IL18 levels. This increase in 
IL16 in pregnant women was found to be associated with 
pre-eclampsia and preterm birth [22–24]. Kuzmicki et al. 
have shown that the balance between circulating pro- and 
anti-inflammatory cytokines is impaired in patients with GDM. 






N = 48 TT vs. CT
Mean ± SD Mean ± SD p&
Body mass before pregnancy [kg] 69.0 ± 16.9 66.4 ± 14.6 0.36
Body mass at birth [kg] 80.6 ± 17.6 76.1 ± 15.2 0.091
Body mass increase during pregnancy [kg] 11.5 ± 5.3 9.8 ± 4.8 0.027
BMI before pregnancy [kg/m2] 25.4 ± 5.8 24.4 ± 4.8 0.31
BMI at birth [kg/m2] 29.7 ± 6.1 28.0 ± 5.1 0.053
BMI increase during pregnancy [kg/m2] 4.3 ± 2.0 3.6 ± 1.8 0.021
HbA1c [%] 5.56 ± 0.48 5.57 ± 0.45 0.99
Daily insulin requirement [unit] 5.07 ± 10.93 6.06 ± 13.17 0.97
Childbirth [weeks] 38.5 ± 1.8 38.4 ± 2.2 0.75
Newborn body mass [g] 3267 ± 627 3272 ± 649 0.90
APGAR (0–10) 9.7 ± 1.0 9.8 ± 1.0 0.41
&Mann-Whitney U test








N = 14 CC vs. CG CC vs. GG CG vs. GG
Mean ± SD Mean ± SD Mean ± SD p&
Body mass before pregnancy [kg] 67.6 ± 15.9 70.2 ± 17.6 62.9 ± 12.1 0.27 0.31 0.11
Body mass at birth [kg] 78.3 ± 16.4 82.2 ± 18.5 72.8 ± 12.1 0.11 0.28 0.059
Body mass increase during pregnancy [kg] 10.6 ± 5.4 12.0 ± 5.1 9.9 ± 3.9 0.013 0.91 0.12
BMI before pregnancy [kg/m2] 24.9 ± 5.0 25.8 ± 6.2 23.6 ± 4.9 0.41 0.29 0.17
BMI at birth [kg/m2] 28.8 ± 5.4 30.2 ± 6.5 27.3 ± 5.0 0.23 0.30 0.12
BMI increase during pregnancy [kg/m2] 4.0 ± 2.1 4.4 ± 1.8 3.7 ± 1.5 0.019 0.94 0.14
HbA1c [%] 5.57 ± 0.45 5.59 ± 0.50 5.29 ± 0.51 0.61 0.051 0.049
Daily insulin requirement [unit] 5.17 ± 11.05 5.64 ± 12.09 4.07 ± 11.45 0.51 0.32 0.54
Childbirth [weeks] 38.3 ± 2.3 38.7 ± 1.2 38.9 ± 1.2 0.79 0.38 0.48
Newborn body mass [g] 3189 ± 713 3381 ± 505 3182 ± 527 0.094 0.56 0.14
APGAR (0–10) 9.6 ± 1.2 9.8 ± 0.6 10.0 ± 0.0 0.26 0.13 0.22
&Mann-Whitney U test
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Increased IL18 levels were detected in women with GDM and 
correlated with maternal obesity [25]. Fatima et al. found that 
increased IL18 levels in women with GDM were correlated 
with low-grade inflammation and insulin resistance [26]. 
IL18 gene polymorphisms have been investigated among 
patients with type 1 and type 2 diabetes [27–31]. Several stud-
ies suggest that these polymorphisms may be associated with 
an increased risk of diabetes and its cardiovascular complica-
tions. These polymorphisms were also studied in patients with 
obesity and it has been found that IL18 gene polymorphisms 
may be associated with obesity and low-grade inflamma-
tion [32, 33]. In our study, we also observed the associations 
between IL18 rs187238 and rs1946518 gene polymorphisms 
and BMI in pregnant women. 
CONCLUSIONS
The results of this study suggest that IL16 rs4778889, 
IL18 rs187238 and rs1946518 polymorphisms may affect the 
risk of GDM as well as BMI in pregnant women. However, 
this observation requires further investigation in women 
of other populations. 
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